These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26407760)

  • 21. Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups.
    Pavelek Z; Novotny M; Soucek O; Krejsek J; Sobisek L; Sejkorova I; Masopust J; Kuca K; Valis M; Klimova B; Stourac P
    Mult Scler Relat Disord; 2021 Aug; 53():103082. PubMed ID: 34166982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.
    Dhib-Jalbut S; Chen M; Said A; Zhan M; Johnson KP; Martin R
    J Neuroimmunol; 2003 Jul; 140(1-2):163-71. PubMed ID: 12864985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate.
    Ebrahimi Monfared M; Shapoori S; Mosayebi G; Khansarinejad B; Ghazavi A; Rezagholizamenjany M; Ganji A
    Neuroimmunomodulation; 2019; 26(6):301-306. PubMed ID: 31935737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global DNA Methylation and Hydroxymethylation Levels in PBMCs Are Altered in RRMS Patients Treated with IFN-β and GA-A Preliminary Study.
    Reyes-Mata MP; Mireles-Ramírez MA; Griñán-Ferré C; Pallàs M; Pavón L; Guerrero-García JJ; Ortuño-Sahagún D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.
    Boster AL; Ford CC; Neudorfer O; Gilgun-Sherki Y
    Expert Rev Neurother; 2015 Jun; 15(6):575-86. PubMed ID: 25924547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
    Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP
    Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
    Izquierdo G; García-Agua Soler N; Rus M; García-Ruiz AJ
    Brain Behav; 2015 Jun; 5(6):e00337. PubMed ID: 26085963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glatiramer acetate treatment normalized the monocyte activation profile in MS patients to that of healthy controls.
    Chuluundorj D; Harding SA; Abernethy D; La Flamme AC
    Immunol Cell Biol; 2017 Mar; 95(3):297-305. PubMed ID: 27694998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RGC-32 and diseases: the first 20 years.
    Vlaicu SI; Tatomir A; Anselmo F; Boodhoo D; Chira R; Rus V; Rus H
    Immunol Res; 2019 Jun; 67(2-3):267-279. PubMed ID: 31250246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.
    Kulakova O; Bashinskaya V; Kiselev I; Baulina N; Tsareva E; Nikolaev R; Kozin M; Shchur S; Favorov A; Boyko A; Favorova O
    Pharmacogenomics; 2017 Nov; 18(17):1563-1574. PubMed ID: 29095108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
    Matute-Blanch C; Río J; Villar LM; Midaglia L; Malhotra S; Álvarez-Cermeño JC; Vidal-Jordana A; Montalban X; Comabella M
    J Neuroimmunol; 2017 Feb; 303():62-65. PubMed ID: 28063616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
    Rovituso DM; Duffy CE; Schroeter M; Kaiser CC; Kleinschnitz C; Bayas A; Elsner R; Kuerten S
    Sci Rep; 2015 Sep; 5():14265. PubMed ID: 26387426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells.
    Fosbrink M; Cudrici C; Tegla CA; Soloviova K; Ito T; Vlaicu S; Rus V; Niculescu F; Rus H
    Exp Mol Pathol; 2009 Apr; 86(2):87-94. PubMed ID: 19162005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
    Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R
    Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.